BankPlus Trust Department Increases Position in Thermo Fisher Scientific Inc. $TMO

BankPlus Trust Department increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.6% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,752 shares of the medical research company’s stock after purchasing an additional 121 shares during the quarter. BankPlus Trust Department’s holdings in Thermo Fisher Scientific were worth $1,116,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the stock. Revolve Wealth Partners LLC increased its holdings in shares of Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after purchasing an additional 20 shares in the last quarter. Root Financial Partners LLC increased its holdings in shares of Thermo Fisher Scientific by 5.0% in the 1st quarter. Root Financial Partners LLC now owns 506 shares of the medical research company’s stock valued at $252,000 after purchasing an additional 24 shares in the last quarter. Rossmore Private Capital grew its stake in Thermo Fisher Scientific by 0.5% in the 1st quarter. Rossmore Private Capital now owns 4,652 shares of the medical research company’s stock valued at $2,315,000 after acquiring an additional 24 shares during the last quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH grew its stake in Thermo Fisher Scientific by 3.1% in the 2nd quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH now owns 803 shares of the medical research company’s stock valued at $326,000 after acquiring an additional 24 shares during the last quarter. Finally, Family Legacy Inc. grew its stake in Thermo Fisher Scientific by 1.0% in the 1st quarter. Family Legacy Inc. now owns 2,690 shares of the medical research company’s stock valued at $1,339,000 after acquiring an additional 26 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insider Activity at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the sale, the executive vice president directly owned 22,367 shares of the company’s stock, valued at approximately $10,735,712.66. This trade represents a 1.76% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Marc N. Casper sold 400 shares of the firm’s stock in a transaction on Friday, September 5th. The shares were sold at an average price of $500.50, for a total transaction of $200,200.00. Following the sale, the chief executive officer directly owned 113,762 shares of the company’s stock, valued at approximately $56,937,881. The trade was a 0.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 30,066 shares of company stock valued at $14,182,963. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock opened at $539.54 on Wednesday. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $610.97. The firm has a fifty day moving average of $484.90 and a 200-day moving average of $447.60. The firm has a market capitalization of $203.73 billion, a P/E ratio of 31.21, a PEG ratio of 2.95 and a beta of 0.77. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating analysts’ consensus estimates of $5.22 by $0.14. The business had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business’s revenue was up 2.9% on a year-over-year basis. During the same period last year, the business earned $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.95%.

Wall Street Analyst Weigh In

TMO has been the topic of a number of research reports. Evercore ISI increased their price objective on shares of Thermo Fisher Scientific from $525.00 to $590.00 and gave the company an “outperform” rating in a research note on Tuesday. Hsbc Global Res cut shares of Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 24th. William Blair assumed coverage on shares of Thermo Fisher Scientific in a research note on Monday, August 18th. They set an “outperform” rating on the stock. Scotiabank raised shares of Thermo Fisher Scientific from a “sector perform” rating to a “sector outperform” rating and set a $590.00 price objective for the company in a research report on Friday, July 11th. Finally, UBS Group increased their price target on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a “neutral” rating in a research note on Thursday, July 24th. Fifteen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and a consensus price target of $591.16.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.